Immunoglobulin G Fc-receptor (Fc gamma R) IIA and IIIB polymorphisms related to disability in MS

Citation
Km. Myhr et al., Immunoglobulin G Fc-receptor (Fc gamma R) IIA and IIIB polymorphisms related to disability in MS, NEUROLOGY, 52(9), 1999, pp. 1771-1776
Citations number
35
Categorie Soggetti
Neurology,"Neurosciences & Behavoir
Journal title
NEUROLOGY
ISSN journal
00283878 → ACNP
Volume
52
Issue
9
Year of publication
1999
Pages
1771 - 1776
Database
ISI
SICI code
0028-3878(19990610)52:9<1771:IGF(GR>2.0.ZU;2-M
Abstract
Objective: MS is immunologically mediated in genetically susceptible indivi duals. Receptors for the Fc fragment of immunoglobulin G (IgG) (Fc gamma R) link the humoral and cellular immune responses by targeting immune complex es to effector cells. Different Fc gamma R show variability in their distri bution, strength, and capacity of binding different IgG subclasses. Methods : To investigate the role of Fc gamma R in MS, 136 MS patients and 96 match ed controls were genotyped for Fc gamma RIIA and Fc gamma RIIIB gene polymo rphisms; the results were correlated to disease susceptibility and severity measured by the Expanded Disability Status Scale (EDSS). Results: The alle le frequencies of the Fc gamma RIIA and Fc gamma RIIIB did not differ signi ficantly between the MS patients and the controls. Patients homozygous for the Fc gamma RIIIB neutrophil antigen (NA) I allele had a significantly mor e benign course of MS than patients heterozygous or homozygous for the Fc g amma RIIIB NA2 allele. Patients homozygous for the Fc gamma RIIA histidine (H) allele also had a more benign course of MS than patients heterozygous o r homozygous for the Fc gamma RIIA arginine (R) allele. Conclusion: The res ults implicate Fc gamma RIIIB and to a lesser extent Fc gamma RIIA as disea se-modifying genes in MS. Fc gamma RIIIB NA1/NA1 and Fc gamma RIIA H/H bind more efficient IgG1/IgG3 and IgG2 subclasses, respectively, than Fc gamma RIIIB NA2/NA2 and Fc gamma RIIA R/R. A more effective processing of circula ting immune complexes may be one mechanism for better clinical outcome in M S.